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Background: Spasticity often leads to symptomatic and functional problems that can cause disability for stroke
survivors. We studied whether spasticity has a negative impact on health-related quality of life (HRQoL).
Methods: As part of the Greater Cincinnati/Northern Kentucky Stroke Study (NCT00642213), 460 ischemic stroke
patients were interviewed during hospitalization and then followed over time. HRQoL was measured by the Physical
Component Summary (PCS) and Mental Component Summary (MCS) scores of the Short Form-12 (SF-12), EuroQol-5
dimension (EQ-5D), and Stroke-Specific Quality of Life (SSQOL) instruments, with lower scores indicating worse health.
HRQoL differences between stroke survivors with and without spasticity were compared, adjusting for age, race, stroke
severity, pre-stroke function, and comorbidities.
Results: Of the 460 ischemic stroke patients, 328 had spasticity data available 3 months after their stroke (mean
age of 66 years, 49 % were female, and 26 % were black). Of these patients, 54 (16 %) reported having spasticity.
Three months following their stroke, patients who reported spasticity had lower mean scores on the PCS (29.6 ± 1.4 vs
37.3 ± 0.6; P < .001), EQ-5D (0.59 ± 0.03 vs 0.71 ± 0.01; P < .001), and SSQOL (3.57 ± 0.08 versus 3.78 ± 0.03; P = .03)
compared with patients who did not report spasticity. Lower HRQoL scores were also observed at the 1-year
(PCS, EQ-5D, and SSQOL) and 2-year (EQ-5D and SSQOL) interviews in those with spasticity compared with those
without spasticity.
Conclusions: Statistically and clinically meaningful differences in HRQoL exist between stroke survivors with and
without spasticity.
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Each year, 15 million people worldwide, including ap-
proximately 795,000 Americans, experience a new or
recurrent stroke [1, 2]. Stroke ranks fourth among all
causes of death and is a leading cause of serious, long-
term disability in the United States [2]. Spasticity, a sen-
sorimotor disorder characterized by a velocity-dependent
increase in muscle tone with exaggerated tendon jerks,* Correspondence: gillard_patrick@allergan.com
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12 months after stroke [3–5].
Although spasticity can be regional or generalized,
stroke survivors commonly experience focal spasticity
in their upper and/or lower limbs. In an analysis by
Urban and colleagues, PSS in the upper and/or lower
limbs occurred in approximately 43 % of patients
6 months after stroke among patients with clinical signs
of central paresis [4]. Stroke survivors with spasticity
often experience secondary limb deformities, physical
disability, and pain that limits their ability to perform basic
activities of daily living, such as holding or picking up
objects, self-care, and ambulation. Stroke survivors withis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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tional issues, such as depression and poor self-image
[6]. As a result, spasticity has been hypothesized to
have a significant negative impact on the health-related
quality of life (HRQoL) of stroke survivors. To date, the
published evidence to support this negative association
is limited [7]. Most existing supportive information
comes from clinical trials that are short in duration and
not generalizable to the United States population.
Given the extent to which spasticity is present in stroke
survivors and the paucity of data examining the impact of
spasticity on stroke survivors’ HRQoL, we utilized a longi-
tudinal cohort study of stroke survivors to examine the
impact of spasticity on HRQoL.
Methods
Study design
This work was undertaken through the Greater Cincinnati/
Northern Kentucky Stroke Study (GCNKSS), a 5-county
population-based study designed to characterize the stroke
population in the greater Cincinnati metropolitan area and
to determine the regional incidence of stroke and mortality.
GCNKSS was approved by the institutional review boards
at all participating institutions. Study methods have been
described elsewhere [8].
Study participants
As part of the 2005 cohort of the GCNKSS, a group of
ischemic stroke patients was prospectively identified
from the larger cohort in order to examine poststroke
clinical and HRQoL outcomes. Ischemic stroke patients
were identified as having had an ischemic stroke based
on the clinical criteria adapted from the Classification of
Neurological Disorders III and epidemiological studies
of stroke for cerebral ischemia and a review of medical
records, including all available neuroimaging. All adult
(≥18 years of age) ischemic stroke patients who presented
during 2005 at any of the 17 hospitals in the study area
were eligible for study enrollment if they resided in
the 5 study area counties.
After a potential patient was identified, the patient’s
treating physician was contacted for permission to ap-
proach the individual for informed consent. Written
informed consent was obtained either from the patient
or from a proxy for patients who were unable to supply
reliable information or were unresponsive, aphasic, or
confused. Patients unable to be interviewed or provide
informed consent (independently or by proxy) and pa-
tients diagnosed with a terminal illness prior to stroke
with a life expectancy of <12 months were not enrolled
in the study.
For each enrolled patient, detailed medical record ab-
stractions were undertaken by trained nurses to capture
key information about demographics, pre-stroke level offunctioning, past medical history, and testing and la-
boratory results. Stroke severity was estimated from the
medical record using the retrospective National Insti-
tutes of Health Stroke Scale (rNIHSS) score [9]. To
assess functional and HRQoL outcomes, a detailed in-
person interview was performed in the early poststroke
period, and phone interviews were conducted at 3 months,
1 year, and 2 years poststroke in surviving cohort mem-
bers. Interviews were conducted by trained study nurses.
Comorbidities and other medical conditions were first
identified by retrospective review of hospital charts during
the 3-month poststroke period and by phone interview at
3 months, 1 year, and 2 years. Details of the interviews
have been published previously [10].
As part of the 3-month and annual interviews, each
surviving poststroke patient was asked if he or she had
experienced spasticity following his or her stroke (e.g.,
“Did you have any spasticity following your stroke?”). The
interviewer explained the term “spasticity” as if the patient
did not recognize the term. For this analysis, if the patient
answered “yes” to this question, he or she was classified as
a poststroke patient with spasticity. A patient who an-
swered “no” to the spasticity question was classified as a
poststroke patient without spasticity. At different time
points (3 months, 1 year, and 2 years), poststroke patients
would be reclassified as with or without spasticity depend-
ing on their answer to the same question.Outcome measures
Three instruments were used to assess HRQoL. As part of
each poststroke interview, the interviewer administered
the EuroQol-5 dimension (EQ-5D), the Short Form-12
(SF-12), and the Stroke-Specific Quality of Life (SSQOL)
instruments.
The EQ-5D (3 levels) is a widely used preference-
based generic HRQoL measure that consists of 2 com-
ponents, the self-classifier and the visual analog scale.
The self-classifier (the section of the EQ-5D used in
this analysis) provides a simple method for capturing
self-reported descriptions of health problems according
to a 5-dimension classification system. The 5 dimen-
sions include mobility, self-care, usual activities, pain/
discomfort, and anxiety/depression. Each dimension
comprises the following 3 levels: (1) no problem, (2)
some or moderate problems, and (3) severe or extreme
problems. Scores for the 5 dimensions were converted
into a utility index that ranges between −0.11 and 1
(United States–weighted) by applying the scores from
value sets (i.e., preference weights) elicited from the
United States population [11, 12]. A maximum score of 1
indicates perfect health, whereas a score of 0 represents
death. A negative score is indicative of health states worse
than death (i.e., an individual would prefer death versus
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validity of the EQ-5D in the stroke population [13].
The SF-12 is also a widely used generic HRQoL in-
strument derived from the Short Form-36. The SF-12
includes 12 questions that represent the following 8
health domains: Physical Functioning, Role Limitations
due to Physical Health, Bodily Pain, General Health,
Vitality, Social Functioning, Role Limitations due to
Emotional Problems, and Mental Health. Weighted scores
from the 8 health domains were aggregated into the Phys-
ical Component Summary (PCS) and the Mental Compo-
nent Summary (MCS) scores. Scores were normalized for
age and sex, resulting in SF-12 scores centered around 50,
reflecting the average domain scores of the United States
population. Scores >50 indicate better HRQoL, whereas
scores <50 denote worse HRQoL [14]. The SF-12 has been
shown to be valid in the stroke population.
Unlike the EQ-5D and the SF-12, the SSQOL is a
stroke-specific HRQoL instrument that has been validated
for telephone data gathering [15]. Although the SSQOL
cannot measure HRQoL across populations and across
diseases, it may capture important disease-specific infor-
mation not captured by the generic instruments. A re-
duced version of the SSQOL consists of 35 items that
measure the following 7 health domains: Energy, Role
Function, Language, Physical Function, Mood, Thinking,
and Vision [16]. Each item is measured on a 5-point Likert
scale using 1 of 3 different response sets (e.g. “no trouble
at all” to “couldn’t do it at all” for task-oriented items).
The overall score was computed as an unweighted average
of the domain scores, with higher scores indicating better
HRQoL. Although this shortened form of the stroke-
specific instrument has not been published, other short-
ened forms of the stroke-specific instrument have been
published [17].
Statistical analysis
Demographic and baseline clinical characteristics of the
stroke cohort were assessed using descriptive statistics
and were compared between stroke survivors with and
without 3-month spasticity using 2-sample t-tests for age;
Chi-square test for sex, race, marital status, employment
status, smoking status, education, and baseline comorbid
conditions; Wilcoxon rank sum test for body mass index,
modified Rankin Scale (mRS), lesion volume, and rNIHSS;
and Fisher’s exact test for residence status at admission. A
cross-sectional approach was used to evaluate differences
in mean HRQoL instrument scores between stroke pa-
tients with and without spasticity at each time point
(3 months, 1 year, and 2 years) using multivariable linear
regression models, adjusting for age, race, stroke severity
(rNIHSS), pre-stroke function (mRS), and time-specific
comorbidities. The SF-12 was not collected at the 2 year
follow-up by design to limit the length of the interviewquestionnaire. As such, analyses using the SF-12 are
limited to 3 months and 1 year follow-up. This was
followed by linear regression models for longitudinal
measures of HRQoL in association with spasticity using
generalized estimating equations to account for repeated
measurements. This modeling approach accommodates
missing data and allows for the use of all data points avail-
able to estimate a model, potentially minimizing bias from
missing data [18]. Spasticity status was included in the
models as a time-varying independent variable. Age, race,
rNIHSS, and pre-stroke mRS were included as time-
invariant covariates. Comorbidities of cardiovascular dis-
ease, diabetes, depression, seizure, and infection in the
prior month were included as time-varying covariates.
Analyses were conducted using SAS software (version 9.3;
SAS Institute Inc., Cary, NC).
Results
A total of 460 ischemic stroke patients were enrolled in
the 2005 cohort. The mean (± standard deviation [SD])
age was 67 ± 14 years, 48 % were female, and 25 % were
black. At 3 months poststroke, 328 had spasticity data
available and 54 (16 %) reported having spasticity. At
3 months, the mean age of patients with spasticity was
lower than those who did not report spasticity (60 vs
67 years), a higher proportion of patients with spasticity
was black (39 % vs 23 %), and a higher proportion was
on disability (22 % vs 7 %) (Table 1). Employment status
at 3 months poststroke differed significantly between pa-
tients with spatisticy and patients without spasticity with
a higher proportion employed (33 % vs 29 %) and on dis-
ability (22 % vs 7 %) and a lower proportion unemployed
(44 % vs 64 %) for those with spasticity compared to those
without spasticity (P < .01). In addition, a higher propor-
tion of patients with spasticity had a seizure history (15 %
vs 4 %) and patients with spasticity had a more severe
stroke (median rNIHSS 6 vs 4) compared with those pa-
tients without spasticity (Table 2). At 1 year poststroke,
243 patients had spasticity data available and 43 (18 %)
reported having spasticity. Thirty eight (16 %) patients
changed spasticity status [19 (8 %) present to absent; 19
(8 %) absent to present]. At 2 years poststroke, 187 pa-
tients had spasticity data available and 31 (17 %) reported
having spasticity. Twenty five (13 %) patients changed
spasticity status [14 (7 %) present to absent; 11 (6 %) ab-
sent to present]. Over the 3 poststroke time points, 365
patients had spasticity data available at some point during
follow-up, and those patients were included in the longitu-
dinal HRQoL models. Of the 365 patients included in the
longitudinal models, 91 patients reported having spasticity
at least once.
The mean (± standard error [SE]) PCS score was lower
for patients who reported spasticity at 3 months than for
those who did not report spasticity (29.6 ± 1.4 vs 37.3 ± 0.6,
Table 1 Sociodemographic characteristics of the stroke cohort
All poststroke patients Patients with spasticity dataa Patients with spasticitya Patients without spasticitya P value*
N 460 328 54 274
Age, mean ± SD, y 67.0 ± 14.0 65.8 ± 13.9 59.7 ± 14.1 67.1 ± 13.5 <.01
Female, n (%) 219 (47.6) 159 (48.5) 25 (46.0) 134 (49.0) .73
Black, n (%) 113 (24.6) 84 (25.6) 21 (38.9) 63 (23.0) .01
Residence at admission, n (%)
Home 437 (95.0) 312 (95.1) 51 (94.4) 261 (95.3) .73
Not home 23 (5.0) 16 (4.9) 3 (5.6) 13 (4.7)
Marital status, n (%)
Married/Partner 236 (51.3) 167 (50.9) 25 (46.3) 142 (51.8) .46
Single 224 (48.7) 161 (49.1) 29 (53.7) 132 (48.2)
Employment status, n (%) < .01
Employed 131 (28.5) 97 (29.6) 18 (33.3) 79 (28.8)
Unemployed/Retired/Other 290 (63.0) 199 (60.7) 24 (44.4) 175 (63.9)
On disability 39 (8.5) 32 (9.8) 12 (22.2) 20 (7.3)
Education .93
<HS 153 (33.5) 102 (31.2) 18 (33.3) 84 (30.8)
HS/GED test 127 (27.9) 93 (28.4) 15 (27.8) 78 (28.6)
Some college 176 (38.6) 132 (40.4) 21 (38.9) 111 (40.7)
Abbreviations: GED general education development, HS high school, SD standard deviation
aAt 3 months
*Comparison between patients with and without spasticity
Table 2 Clinical characteristics of the stroke cohort
All poststroke patients Patients with spasticity dataa Patients with spasticitya Patients without spasticitya P value*
N 460 328 54 274
BMI, median (IQR) 27.4 (24.2–31.5) 27.9 (24.6–32.3) 28.1 (24.4–33.8) 27.9 (24.6–31.7) .50
Current smoker, n (%) 143 (31.0) 103 (31.0) 19 (35.0) 84 (31.0) .51
Comorbidities, n (%)
Cardiovascular 201 (43.7) 134 (41.0) 20 (37.0) 114 (41.6) .53
Diabetes 164 (35.6) 115 (35.0) 21 (38.9) 94 (34.3) .52
Depression (CESD ≥10) 180 (39.2) 125 (38.0) 24 (44.4) 101(36.9) .29
Seizure 30 (6.5) 20 (6.0) 8 (14.8) 12 (4.4) .01
Infection 82 (17.9) 54 (17.0) 8 (14.8) 46 (16.8) .71
Prestroke Rankin (pre-
mRS), median (IQR)
1 (0, 2) 1 (0, 2) 1 (0, 2) 1 (0, 2) .68
Lesion volume, median
(IQR)
N = 205 N = 143 N = 23 N = 120 .20
2 (0–14) 2 (0–16) 2 (1–39) 2 (0–12)
Estimated rNIHSS, median
(IQR)
4 (2–7) 4 (2–7) 6 (3–10) 4 (2–6) .02
Abbreviations: BMI body mass index, CESD Center for Epidemiologic Studies Depression scale, IQR interquartile range, mRS modified Rankin Scale, rNIHSS
retrospective National Institute of Health Stroke Scale
aAt 3 months
*Comparison between patients with and without spasticity
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interval [CI] [8] –10.7 to −4.6; P < .001). A significant
difference between spasticity groups was not observed
in 3-month mean MCS scores (50.3 ± 1.4 vs 49.5 ± 0.6;
mean difference 0.8; 95 % CI −2.2 to 3.8; P = .59). Simi-
lar results were observed for PCS and MCS mean
scores at 1 year (Fig. 1). Lower EQ-5D scores were re-
ported by those with spasticity than without spasticity
at 3 months (0.59 ± 0.03 vs 0.71 ± 0.01; mean differenceFig. 1 Adjusted mean Short Form-12 (SF-12) scores, by patient-reported spas
(PCS) and Mental Component Summary (MCS) scores were reported by surviv
difference, −7.7; 95 % confidence interval [CI] –10.7 to −4.6; P < .001 and mea
PCS difference −6.9; 95 % CI −10.3 to −3.6; P < .001 and mean MCS differe
administered at the 2-year interview. Scores were adjusted for age, race,
Stroke Scale, prestroke function using the modified Rankin Scale, and com−0.12; 95 % CI −0.18 to −0.06; P < .001) and at 1 and
2 years (Fig. 2). SSQOL scores were also lower in those
with spasticity compared with those without spasticity
at 3 months (3.57 ± 0.08 vs 3.78 ± 0.03; mean differ-
ence −0.20; 95 % CI −0.38 to −0.02; P = .03), as well
as at 1 and 2 years (Fig. 3). In the longitudinal
models, the effects of spasticity did not vary by followup
time (i.e., the impact of spasticity on HRQoL did not vary
significantly from 3 months to 1 year or 1 year to 2 years).ticity presence. Significantly lower mean Physical Component Summary
ors with spasticity than those without spasticity at 3 months (mean PCS
n MCS difference 0.8; 95 % CI, −2.2 to 3.8; P = .59) and at 1 year (mean
nce 0.1; 95 % CI −3.3 to 3.5; P = .96) poststroke. The SF-12 was not
stroke severity using the retrospective National Institute of Health
orbidities
Fig. 2 Adjusted mean EuroQol-5 dimension (EQ-5D) scores by patient-reported spasticity presence. Significantly lower EQ-5D scores were reported by
survivors with spasticity than those without spasticity at 3 months (mean difference −0.12; 95 % confidence interval [CI] –0.18 to −0.06; P < .001), at
1 year (mean difference −0.12; 95 % CI −0.19 to −0.06; P < .001), and at 2 years (mean difference −0.08; 95 % CI −0.16 to −0.0004; P = .049) poststroke.
Scores were adjusted for age, race, stroke severity using the retrospective National Institute of Health Stroke Scale, prestroke function using
the modified Rankin Scale, and comorbidities
Gillard et al. Health and Quality of Life Outcomes  (2015) 13:159 Page 6 of 9Therefore, an average effect of spasticity over the followup
time is presented in Table 3.
Discussion
Stroke causes a decrease in HRQoL with multiple factors,
such as age, gender, dependency in activities of daily living,
social support, depression, institutionalization, and dia-
betes associated with poorer HRQoL in stroke survivors
[19]. The results of this study demonstrate that the pres-
ence of spasticity also independently impacts the HRQoL
of stroke survivors. Stroke survivors with spasticity wereassociated with lower HRQoL compared with stroke sur-
vivors without spasticity.
Although minimal clinically important differences
(MCID; the smallest difference in score that would be
considered meaningful by a patient) for the EQ-5D, SF-
12, and SSQOL have not been established in the stroke
population, the differences in EQ-5D scores observed
in this study between stroke survivors with spasticity and
without spasticity met MCIDs established in other dis-
eases. For example, Walters and Brazier estimated the
average MCID of the EQ-5D to be 0.07 across studies that
Fig. 3 Adjusted mean Stroke-Specific Quality of Life (SSQOL) scores by patient-reported spasticity presence. Significantly lower SSQOL scores were
reported by survivors with spasticity than those without spasticity at 3 months (mean difference −0.20; 95 % CI −0.38 to −0.02; P = .03), at 1 year
(mean difference −0.51; 95 % CI −0.70 to −0.32; P < .001), and at 2 years (mean difference −0.30; 95 % CI −0.52 to −0.09; P = .01) poststroke. Scores
were adjusted for age, race, stroke severity using the retrospective National Institute of Health Stroke Scale, prestroke function using the modified
Rankin Scale, and comorbidities
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arthritis, osteoarthritis, irritable bowel, acute myocardial
infarction, and chronic obstructive pulmonary disease,
and Le et al. recently estimated the MCID of the EQ-5D
to range from 0.3 to 0.1 in patients with posttraumatic
stress disorder [20, 21]. In our study, the mean EQ-5D
differences between patients with and without spasticity at
3 months, 1 year, and 2 years were 0.12, 0.12, and 0.08, re-
spectively. To clinicians who manage stroke survivors with
spasticity, these meaningful differences likely do not come
as a surprise given the day-to-day effect that spasticity hason individuals suffering from this condition. When indi-
viduals with spasticity have been asked which single aspect
of spasticity has the greatest impact on their HRQoL, the
most common answers were limited range of motion,
stiffness or contracture of muscles, and limitations in ac-
tivities of daily living [7]. To our knowledge, the results of
this study are the first to quantify the impact of poststroke
spasticity on HRQoL.
The implications of these results are 3-fold. First, spas-
ticity must be prevented if at all possible and identified
once presenting in stroke survivors. Unfortunately, little
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Overall score 3.6 ± 0.05 3.8 ± 0.03 −0.21
(–0.32 to–0.11)
(3.5–3.7) (3.8–3.9)
Abbreviations: CI confidence interval, EQ-5D EuroQol-5 dimension, HRQoL
health-related quality of life, SF-12 Short Form-12, SE standard error, SSQOL
Stroke-Specific Quality of Life, and US United States
aAdjusted for age, race, and retrospective National Institute of Health Stroke Scale
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measure to identify spasticity does not exist. Future work
to understand the predictors of spasticity and improve the
identification of spasticity is needed, specifically in the
community setting. Second, once identified, a stroke sur-
vivor with spasticity should be assessed for treatment or
be referred to a physician educated in spasticity manage-
ment. Last, if treatment is required, a multidisciplinary
approach needs to be taken in order for the patient to get
the most benefit from existing treatments. Potential treat-
ments include physical rehabilitation, oral medications,
botulinum toxin A, phenol, and surgery.
There are limitations to this study. The findings may
not be generalizable to all ischemic stroke patients
since study participates had to survive their stroke
hospitalization and reside in the Greater Cincinnati/
Northern Kentucky region. The prevalence of spasti-
city in the cohort was 16 % at 3 months poststroke,
lower than rates reported in other studies. This may be
in part due to spasticity being patient-reported, which
may have led to the classification of stoke survivors as
nonspastic when indeed spasticity was present. Also,
the study did not examine current use of spasticity
medication and did not include a spasticity-specific
HRQoL measure. The validation of the shortened
version of the stroke-specific instrument (SSQOL)
used in this study has not been published. As is the
case for all observational studies, all confounding fac-
tors may not have been controlled for, but a diligentattempt was made to adjust for known confounders,
such as age, race, stroke severity, pre-stroke function,
and comorbidities.
Conclusions
Spasticity is associated with a negative impact on the
HRQoL of stroke survivors with statistically and clinically
meaningful differences existing between stroke survivors
with and without spasticity. These results suggest an op-
portunity to improve HRQoL among stroke survivors with
spasticity.
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